Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 62Neoplasm Metastasis 10Stomach Neoplasms 9Brain Neoplasms 6Neoplasms 4HER2-positive Breast Cancer 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms, Male 4Lung Neoplasms 3Inflammatory Breast Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Meningeal Carcinomatosis 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Sarcoma 1Recurrence 1Pathologic Processes 1Ovarian Neoplasms 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1

Interventions

Cisplatin 3Amifostine 3Radiotherapy 2Paclitaxel 2sodium thiosulfate 1selinexor 1Trastuzumab 1Topotecan 1Pharmaceutical Preparations 1Nivolumab 1Methotrexate 1Imatinib Mesylate 1Filgrastim 1Etoposide 1Drug Combinations 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Drug-Related Side Effects and Adverse Reactions × Trastuzumab × Clear all
NCT00397501 2017-04-21

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

OHSU Knight Cancer Institute

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡